Lyrica® works as a neurotransmitters blocker, regulates the hyper-excited neurons back to normal threshold1-2. Lyrica® has been approved in the USA and EU3-4 .
- Kavoussi, Richard. "Pregabalin: From Molecule to Medicine." European Neuropsychopharmacology 16.2 (2006): S128-133. Web.
- Lyrica® (pregabalin) Prescribing Information. Pfizer Corporation Hong Kong Limited: version January 2018.
- US. Food and Drug Administration. Approved drug products: Lyrica Pregabalin. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021446. Accessed on 19 June 2019
- European Medicine Agency. Lyrica Pregabalin authorization details. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica. Accessed on 18 June 2019.